Chemical Structure (Sumatriptan Usp 1)
Sumatriptan
Product Images NDC 33261-663
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 33261-663). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Usp 2)
Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Usp 3)
Estimated Probability of Remedication or Rescue: 100% based on the dosage and type of medication used. The text also includes a table with different dosages of medication, including a placebo option. The last line of the text appears to be cut off and is not readable.*
Image Description (Sumatriptan Usp 4)
This appears to be information about a medication called "Sumatriptan, USP" in different dosages and forms including a spray and tablet. The medication is also referred to as a generic for "Imitrex" and is made by a company named Aurbindo Pharma Ltd. It is unclear what the medication is used for or the potential side effects as the provided text is incomplete and difficult to understand in places due to errors.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
